CRISPR Therapeutics and Intellia Therapeutics are two of the most closely watched names in the gene-editing sector, both built on CRISPR/Cas9 (a gene-editing technology that can precisely modify DNA sequences). Although they share a technology platform, they differ sharply in stage of development, pipeline focus, and market capitalization. For traders and investors evaluating biotechnology exposure, this stock comparison highlights how relative performance, momentum, and catalyst timelines can diverge between two companies in the same industry. Understanding those differences matters for anyone assessing risk tolerance, time horizon, and market positioning in an inherently volatile corner of healthcare.
CRISPR Therapeutics is a Switzerland-based gene-editing company best known for CASGEVY, the first CRISPR/Cas9-based therapy to receive U.S. FDA (Food and Drug Administration) approval, developed in partnership with Vertex Pharmaceuticals to treat sickle cell disease and transfusion-dependent beta-thalassemia. This gives CRSP a commercial revenue stream that most gene-editing peers do not yet have.
In recent weeks, the stock has traded lower, setting fresh 52-week lows despite reporting quarterly revenue growth of more than 1,300% year over year, driven by CASGEVY. The company has continued to post widening net losses as it funds pipeline expansion, but a cash and investment balance reported in the range of roughly $1.9 billion to $2.4 billion provides a multi-year runway. Recent data presentations, including Phase 1b cardiovascular results and early autoimmune data, have drawn mixed reactions from the market. Analyst sentiment remains broadly positive, with a consensus Buy rating, though near-term momentum has stayed weak.
Intellia Therapeutics is a clinical-stage genome-editing company focused on in vivo (inside the body) CRISPR/Cas9 therapies, with lead programs targeting hereditary angioedema (lonvo-z) and ATTR amyloidosis (nex-z). It maintains collaborations with Regeneron and Novartis. Unlike CRSP, NTLA does not yet have an approved product, though it is advancing toward a potential first approval with a BLA (Biologics License Application) for lonvo-z under priority review.
Recent market activity has been volatile. The stock rallied after the FDA lifted a clinical hold on the late-stage MAGNITUDE-2 study, but subsequently pulled back following a quarterly report that showed revenue declining sharply year over year and a widened net loss. Enrollment completion in a Phase 3 ATTR trial and positive long-term follow-up data have supported the pipeline narrative, yet the stock remains well below its 52-week high. Analyst consensus is Hold, reflecting a mix of optimism around late-stage catalysts and caution over continued losses and execution risk.
Tickeron's Trending AI Robots page curates a selection of the platform's AI trading bots, chosen for their suitability to current market conditions. Tickeron offers hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with distinct trading styles, strategies, timeframes, performance statistics, and target ticker lists. Rather than surfacing every available bot, the Trending AI Robots section highlights only those demonstrating the most relevant recent performance and adaptability. This curated approach helps traders filter a broad universe of automated strategies down to a focused set of candidates. Investors comparing stocks like CRSP and NTLA may find value in reviewing these bots to see how data-driven systems are positioning across the market.
The clearest contrast is commercialization. CRSP generates recognized revenue from an approved therapy, while NTLA remains pre-revenue at scale and depends on future regulatory milestones. CRSP also carries a larger market capitalization and a stronger cash position, which supports a longer development runway. NTLA, by comparison, has a smaller balance sheet relative to its operating losses, heightening financing sensitivity.
On growth drivers, CRSP's near-term story hinges on CASGEVY uptake and pipeline readouts, whereas NTLA's hinges on potential approval and launch of lonvo-z and progress in ATTR. Risk profiles differ accordingly: CRSP faces commercial execution and partnership-related revenue recognition constraints, while NTLA faces binary regulatory and clinical outcomes. In terms of recent momentum and market sentiment, both stocks have trended lower, but NTLA's swings have been more pronounced, reflecting its earlier stage and heavier reliance on single catalysts.
Based on observable factors such as trend consistency, stability, catalysts, and relative market positioning, Tickeron's AI framework currently appears to favor CRSP over NTLA. CRSP's commercialized asset base, larger cash runway, and comparatively steadier trend profile provide a more consistent technical and fundamental foundation. While NTLA offers substantial upside potential tied to its late-stage pipeline, its higher volatility and deeper reliance on binary catalysts introduce greater uncertainty. This assessment is probabilistic and reflects current conditions rather than a definitive prediction of future returns.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The 50-day moving average for CRSP moved below the 200-day moving average on November 12, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRSP as a result. In 86 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for CRSP turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 41 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRSP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for CRSP entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRSP advanced for three days, in 210 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
CRSP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.772) is normal, around the industry mean (3.596). P/E Ratio (-10.631) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (454.545) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. CRSP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRSP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
NTLA saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned negative. In 86 of the 94 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for NTLA turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 42 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
NTLA moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NTLA crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 20 of 22 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTLA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTLA advanced for three days, in 206 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
NTLA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.186) is normal, around the industry mean (3.596). P/E Ratio (-3.398) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (23.095) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 52 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. NTLA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NTLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CRSP | NTLA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 63 | 72 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 23 Undervalued | 36 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 98 | |
PRICE GROWTH RATING 1..100 | 78 | 64 | |
P/E GROWTH RATING 1..100 | 56 | 52 | |
SEASONALITY SCORE 1..100 | 50 | 14 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CRSP's Valuation (23) in the Biotechnology industry is in the same range as NTLA (36). This means that CRSP’s stock grew similarly to NTLA’s over the last 12 months.
CRSP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NTLA (100). This means that CRSP’s stock grew similarly to NTLA’s over the last 12 months.
CRSP's SMR Rating (96) in the Biotechnology industry is in the same range as NTLA (98). This means that CRSP’s stock grew similarly to NTLA’s over the last 12 months.
NTLA's Price Growth Rating (64) in the Biotechnology industry is in the same range as CRSP (78). This means that NTLA’s stock grew similarly to CRSP’s over the last 12 months.
NTLA's P/E Growth Rating (52) in the Biotechnology industry is in the same range as CRSP (56). This means that NTLA’s stock grew similarly to CRSP’s over the last 12 months.
| CRSP | NTLA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | N/A |
| Stochastic ODDS (%) | 1 day ago 80% | 1 day ago 81% |
| Momentum ODDS (%) | 1 day ago 88% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 87% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 81% | 1 day ago 79% |
| TrendMonth ODDS (%) | 1 day ago 80% | 1 day ago 90% |
| Advances ODDS (%) | 23 days ago 82% | 12 days ago 79% |
| Declines ODDS (%) | 4 days ago 81% | 2 days ago 88% |
| BollingerBands ODDS (%) | 1 day ago 86% | 1 day ago 84% |
| Aroon ODDS (%) | 1 day ago 85% | N/A |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRSP’s FA Score shows that 1 FA rating(s) are green while NTLA’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRSP’s TA Score shows that 4 TA indicator(s) are bullish while NTLA’s TA Score has 3 bullish TA indicator(s).
CRSP (@Biotechnology) experienced а -8.66% price change this week, while NTLA (@Biotechnology) price change was -9.76% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -8.90%. For the same industry, the average monthly price growth was -16.46%, and the average quarterly price growth was -27.70%.
CRSP is expected to report earnings on Feb 16, 2027.
NTLA is expected to report earnings on Feb 25, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, CRSP has been closely correlated with BEAM. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To CRSP | 1D Price Change % | ||
|---|---|---|---|---|
| CRSP | 100% | +0.44% | ||
| BEAM - CRSP | 77% Closely correlated | -0.19% | ||
| NTLA - CRSP | 75% Closely correlated | +5.04% | ||
| RXRX - CRSP | 66% Closely correlated | -9.93% | ||
| PRME - CRSP | 64% Loosely correlated | -7.55% | ||
| EDIT - CRSP | 64% Loosely correlated | -4.09% | ||
More | ||||
A.I.dvisor indicates that over the last year, NTLA has been closely correlated with CRSP. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To NTLA | 1D Price Change % | ||
|---|---|---|---|---|
| NTLA | 100% | +5.04% | ||
| CRSP - NTLA | 75% Closely correlated | +0.44% | ||
| BEAM - NTLA | 70% Closely correlated | -0.19% | ||
| VCYT - NTLA | 69% Closely correlated | +0.36% | ||
| PRME - NTLA | 61% Loosely correlated | -7.55% | ||
| EDIT - NTLA | 60% Loosely correlated | -4.09% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| VXX | 27.31 | 3.48 | +14.60% |
| iPath Series B S&P 500 VIX Short-Term Futures ETN (VXX) | |||
| MUSE | 47.67 | -0.12 | -0.24% |
| TCW Multisector Credit Income ETF (MUSE) | |||
| UTF | 24.07 | -0.50 | -2.04% |
| Cohen & Steers Infrastructure Fund | |||
| HQGO | 60.18 | -2.56 | -4.08% |
| Hartford US Quality Growth ETF (HQGO) | |||
| WGMI | 20.00 | -3.35 | -14.35% |
| CoinShares Bitcoin Mining and Digital Power ETF (WGMI) | |||